ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
December 27 2022 - 4:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Mark Enyedy, President and CEO, will present
at the upcoming 41st Annual J.P. Morgan Healthcare Conference in
San Francisco, CA. The presentation is scheduled for 3:45pm PT
(6:45pm ET) on January 10, 2023.
Following the presentation, Mr. Enyedy will be joined by other
members of ImmunoGen’s management team for a question-and-answer
session at 4:05pm PT (7:05pm ET).
A webcast of the presentation and question-and-answer session
will be accessible live through the “Investors & Media” section
of the Company’s website, www.immunogen.com; a replay will be
available in the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221227005216/en/
INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600
anabel.chan@immunogen.com
MEDIA ImmunoGen Courtney O'Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024